End of life distress as an economic issue: The case for psychedelic-assisted therapy.

The abstract argues that end-of-life distress should be understood as an economic issue, making the case for psychedelic-assisted therapy as a cost-effective intervention. It suggests that addressing psychological suffering at the end of life with such therapies could reduce healthcare costs and improve patient outcomes, framing the discussion around economic rather than purely clinical or ethical considerations.

Study at a glance

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.